Trials / Completed
CompletedNCT00868192
Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary Peritoneal Carcinoma
Phase II Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian and Primary Peritoneal Carcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 38 (actual)
- Sponsor
- Washington University School of Medicine · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if the combination of bevacizumab and pemetrexed have an effect on recurrent ovarian and primary peritoneal carcinoma by looking at progression and survival at 6 months.
Detailed description
Patients will be treated with pemetrexed 500 mg/m2 IV and Bevacizumab 15 mg/kg IV every 3 weeks.The patient is treated indefinitely until side effects are deemed severe by the investigator or until progression. Disease progression is measured every 6 weeks using RECIST criteria.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pemetrexed | |
| DRUG | Bevacizumab |
Timeline
- Start date
- 2008-05-01
- Primary completion
- 2012-12-01
- Completion
- 2012-12-01
- First posted
- 2009-03-24
- Last updated
- 2014-10-20
- Results posted
- 2014-10-20
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00868192. Inclusion in this directory is not an endorsement.